Phase Ia/Ib dose-escalation study of the anti-TIGIT  tiragolumab as a single agent and in combination with atezolizumab in advanced solid tumors - Johanna C Bendell #AACR20 $RHHBY $MRK $RCUS $MREO $SGEN 2/x

cross over allowed from mono to combo https://t.co/7y4wlXqgwy